Palatin Technologies Inc. (PTN)

[BesaoT35]

A previous post points out that cash on hand per share is at around 40 cents per share. Vyleesi is valued already at a very low level. With some marketing for the peptide this may not be a fact that bremelanatide is indeed a failure.

I wonder about the possibility of a patch.

There is also a pipeline that has some hope justified in it.

I use the bremelanotide peptide myself. It is a bit more of an effect than a placebo effect I think. I wish some of you investors would try it out for yourselves and report about your experience here on IHub.

What would be considered a “Book Value” here for PTN?